Compare Palo Alto Networks Inc (PANW) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palo Alto Networks Inc vs Recursion Pharmaceuticals Inc — how do they compare? Palo Alto Networks Inc trades at $335.38 (market cap $278.85B), while Recursion Pharmaceuticals Inc trades at $3 (market cap $1.63B). The key difference: Palo Alto Networks Inc is far larger — about 171.1× Recursion Pharmaceuticals Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| PANW | RXRX | |
|---|---|---|
Market Cap | $278.85B | $1.63B |
Sector | Technology | Health |
52-Week High | $358.68 | $6.79 |
52-Week Low | $141.67 | $2.84 |
Enterprise Value | $277.81B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palo Alto Networks (PANW) trades at $342.15, down 4.61% today, yet maintains a bullish technical trend with strong analyst support. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.85 surpassing the $0.793 estimate. The company shows robust revenue growth, reaching $9.22B in 2025, and positive cash flow trends, though valuation ratios like a P/E of 303.18 remain elevated. News highlights focus on AI-driven cybersecurity demand and strategic acquisitions, such as the intent to enhance its observability platform announced on July 21, 2026.
Outlook is positive due to strong market positioning in cybersecurity and AI integration, but high valuations and competitive pressures pose risks. Investment opportunity lies in sustained earnings growth and sector tailwinds, while investors should monitor execution on guidance and margin sustainability.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
